These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9883081)

  • 21. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice.
    Van der Ploeg AT; Kroos MA; Willemsen R; Brons NH; Reuser AJ
    J Clin Invest; 1991 Feb; 87(2):513-8. PubMed ID: 1991835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Where do we stand in enzyme replacement therapy in Pompe's disease?
    van der Ploeg AT
    Neuromuscul Disord; 2010 Dec; 20(12):773-4. PubMed ID: 21094929
    [No Abstract]   [Full Text] [Related]  

  • 27. Correction/mutation of acid alpha-D-glucosidase gene by modified single-stranded oligonucleotides: in vitro and in vivo studies.
    Lu IL; Lin CY; Lin SB; Chen ST; Yeh LY; Yang FY; Au LC
    Gene Ther; 2003 Oct; 10(22):1910-6. PubMed ID: 14502220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gingival overgrowth in Pompe disease: a case report.
    de Gijt JP; van Capelle CI; Oosterhuis JW; van der Ploeg AT; van der Wal KG
    J Oral Maxillofac Surg; 2011 Aug; 69(8):2186-90. PubMed ID: 21783002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Enzyme replacement therapy in Pompe's disease].
    Merk T; Wibmer T; Schumann C; Krüger S
    Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry.
    Hermans MM; Kroos MA; Smeitink JA; van der Ploeg AT; Kleijer WJ; Reuser AJ
    Hum Mutat; 1998; 11(3):209-15. PubMed ID: 9521422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II.
    Bijvoet AG; Van Hirtum H; Kroos MA; Van de Kamp EH; Schoneveld O; Visser P; Brakenhoff JP; Weggeman M; van Corven EJ; Van der Ploeg AT; Reuser AJ
    Hum Mol Genet; 1999 Nov; 8(12):2145-53. PubMed ID: 10545593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts.
    Reuser AJ; Kroos M; Willemsen R; Swallow D; Tager JM; Galjaard H
    J Clin Invest; 1987 Jun; 79(6):1689-99. PubMed ID: 3108320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mature 98,000-dalton acid alpha-glucosidase is deficient in Japanese quails with acid maltase deficiency.
    Suhara Y; Ishiura S; Tsukahara T; Sugita H
    Muscle Nerve; 1989 Aug; 12(8):670-8. PubMed ID: 2506448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.
    van Capelle CI; van der Beek NA; Hagemans ML; Arts WF; Hop WC; Lee P; Jaeken J; Frohn-Mulder IM; Merkus PJ; Corzo D; Puga AC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2010 Dec; 20(12):775-82. PubMed ID: 20817528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
    Hahn A; Schmidt D; Hagel KJ; Neubauer BA; Katz N
    Clin Lab; 2006; 52(11-12):615-9. PubMed ID: 17175893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.